

Darolutamide

for treating prostate cancer

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Darolutamide 300 mg tablet in combination with androgen deprivation therapy for treating patients with:
 - high-risk non-metastatic castration-resistant prostate cancer; and
 - metastatic hormone-sensitive prostate cancer

in view of the acceptable pricing proposal by the company and potential cost savings to the healthcare system.

Funding status

Darolutamide 300 mg tablet is recommended for inclusion on the Medication Assistance Fund for the abovementioned indications from 1 November 2024.

Clinical indications, subsidy class and MediShield Life claim limits for darolutamide are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Clinical indication	Subsidy class (implementation date)	MediShield Life claim limit per month (implementation date)
Darolutamide 300 mg tablet	In combination with androgen deprivation therapy for treating patients with high-risk non-metastatic castration-resistant prostate cancer.	MAF (1 Nov 2024)	\$400 (1 Sep 2022)
	In combination with androgen deprivation therapy for treating patients with metastatic hormone-sensitive prostate cancer.	MAF (1 Nov 2024)	\$400 (1 Nov 2024)

Abbreviation: MAF, Medication Assistance Fund.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
 Email: ACE_HTA@moh.gov.sg

In citation, please credit the "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.